Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by mdjbrownon Jun 26, 2024 10:03am
90 Views
Post# 36106804

RE:Organigram Invests in Germany

RE:Organigram Invests in Germany

Globe says Organigram increases holdings in Europe

2024-06-26 08:26 ET - In the News

The Globe and Mail reports in its Wednesday edition that Organigram Holdings has taken a minority stake in European cannabis company Sanity Group through a $21-million investment. A Canadian Press dispatch to The Globe quotes the Moncton-based cannabis producer saying that it may eventually advance another $4.5-million to Sanity through an unsecured convertible note, which made up the bulk of its initial investment. The investment is meant to help Organigram capitalize on the recent legalization of cannabis in Germany, where Sanity is based and holds a roughly 10-per-cent share of the medical marijuana market. The arrangement could also see the companies deepen their presence in Switzerland, where Sanity is involved in a recreational pot pilot and is expected to invest in distribution channels. The investment expands on a 2023 agreement that saw Organigram supply Sanity with medical cannabis for distribution across the market. Organigram will now be able to appoint a representative to Sanity's board. The company's shares closed Tuesday at $2.02, down 14 cents on the Toronto Stock Exchange.
 

<< Previous
Bullboard Posts
Next >>